Cargando…

Gout: will the “King of Diseases” be the first rheumatic disease to be cured?

Gout is the most common inflammatory arthritis in adults in the Western world. Characterized by hyperuricemia and the effects of acute and chronic inflammation in joints and bursa, gout leads to an agonizing, chronically painful arthritis. Arthritis can also be accompanied by urate nephropathy and s...

Descripción completa

Detalles Bibliográficos
Autor principal: Singh, Jasvinder A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105252/
https://www.ncbi.nlm.nih.gov/pubmed/27832792
http://dx.doi.org/10.1186/s12916-016-0732-1
_version_ 1782466867051364352
author Singh, Jasvinder A.
author_facet Singh, Jasvinder A.
author_sort Singh, Jasvinder A.
collection PubMed
description Gout is the most common inflammatory arthritis in adults in the Western world. Characterized by hyperuricemia and the effects of acute and chronic inflammation in joints and bursa, gout leads to an agonizing, chronically painful arthritis. Arthritis can also be accompanied by urate nephropathy and subcutaneous urate deposits (tophi). Exciting new developments in the last decade have brought back the focus on this interesting, crystal-induced chronic inflammatory condition. New insights include the role of NALP3 inflammasome-induced inflammation in acute gout, the characterization of diagnostic signs on ultrasound and dual-energy computed tomography imaging modalities, the recognition of target serum urate less than 6 mg/day as the goal for urate-lowering therapies, and evidence-based treatment guidelines. A better understanding of disease mechanisms has enabled drug discovery – three new urate-lowering drugs have been approved in the last decade, with several more in the pipeline. We now recognize the important role that environment and genetics play in the causation of gout. A focus on the cardiac, renal, and metabolic comorbidities of gout will help translational research and discovery over the next decade.
format Online
Article
Text
id pubmed-5105252
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-51052522016-11-14 Gout: will the “King of Diseases” be the first rheumatic disease to be cured? Singh, Jasvinder A. BMC Med Editorial Gout is the most common inflammatory arthritis in adults in the Western world. Characterized by hyperuricemia and the effects of acute and chronic inflammation in joints and bursa, gout leads to an agonizing, chronically painful arthritis. Arthritis can also be accompanied by urate nephropathy and subcutaneous urate deposits (tophi). Exciting new developments in the last decade have brought back the focus on this interesting, crystal-induced chronic inflammatory condition. New insights include the role of NALP3 inflammasome-induced inflammation in acute gout, the characterization of diagnostic signs on ultrasound and dual-energy computed tomography imaging modalities, the recognition of target serum urate less than 6 mg/day as the goal for urate-lowering therapies, and evidence-based treatment guidelines. A better understanding of disease mechanisms has enabled drug discovery – three new urate-lowering drugs have been approved in the last decade, with several more in the pipeline. We now recognize the important role that environment and genetics play in the causation of gout. A focus on the cardiac, renal, and metabolic comorbidities of gout will help translational research and discovery over the next decade. BioMed Central 2016-11-11 /pmc/articles/PMC5105252/ /pubmed/27832792 http://dx.doi.org/10.1186/s12916-016-0732-1 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Editorial
Singh, Jasvinder A.
Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
title Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
title_full Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
title_fullStr Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
title_full_unstemmed Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
title_short Gout: will the “King of Diseases” be the first rheumatic disease to be cured?
title_sort gout: will the “king of diseases” be the first rheumatic disease to be cured?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105252/
https://www.ncbi.nlm.nih.gov/pubmed/27832792
http://dx.doi.org/10.1186/s12916-016-0732-1
work_keys_str_mv AT singhjasvindera goutwillthekingofdiseasesbethefirstrheumaticdiseasetobecured